Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies

References

• Peng Y, Lin J, Guan J, et al. Ovarian collision tumors: imaging findings, pathological characteristics, diagnosis, and differential diagnosis. Abdom Radiol (NY). 2018;43(8):2156–2168.
   Web of Science ®Google Scholar
• Gong W, Luo S, Hu R, et al. Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China. Zhonghua Yu Fang Yi Xue Za Zhi. 2014;48(5):366–369.24985374
   PubMedGoogle Scholar
• Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068–2075. doi:10.1002/1097-0142(20001115)89:10<2068::aid-cncr6>3.0.co;2-z11066047
   PubMed Web of Science ®Google Scholar
• Polom K, Roviello G, Generali D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. Int J Hyperthermia. 2016;32(3):298–310. doi:10.3109/02656736.2016.114923326984715
   PubMed Web of Science ®Google Scholar
• Bukowska B, Rogalska A, Marczak A. New potential chemotherapy for ovarian cancer - combined therapy with WP 631 and epothilone B. Life Sci. 2016;151:86–92. doi:10.1016/j.lfs.2016.02.09526944437
   PubMed Web of Science ®Google Scholar
• Cowan RA, O’Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia. 2017;33(5):548–553. doi:10.1080/02656736.2017.128306628092994
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17:v7–v12. doi:10.1093/annonc/mdj94116807468
   PubMed Web of Science ®Google Scholar
• Tomita Y, Saito T, Okadome M, Eto T, Ariyoshi K, Shimamoto K. The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer. Int J Clin Oncol. 2014;19(4):662–666. doi:10.1007/s10147-013-0599-523887730
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. A phase 1/2 study combining gemcitabine, pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228–32243. doi:10.18632/oncotarget.477226334096
   PubMed Web of Science ®Google Scholar
• Lilly E. Co: Summary of Product Characteristics: Gemcitabine UK Prescribing Information. Indianapolis: Eli Lilly; 1997.
   Google Scholar
• Xu H, Paxton J, Lim J, et al. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Pharm Res. 2014;31(10):2583–2592. doi:10.1007/s11095-014-1353-z24639234
   PubMed Web of Science ®Google Scholar
• May JP, Ernsting MJ, Undzys E, Li SD. Thermosensitive liposomes for the delivery of gemcitabine and oxaliplatin to tumors. Mol Pharm. 2013;10(12):4499–4508. doi:10.1021/mp400321e24152292
   PubMed Web of Science ®Google Scholar
• Khaira R, Sharma J, Saini V. Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride. ScientificWorldJournal. 2014;2014:560962. doi:10.1155/2014/56096224592173
   PubMed Web of Science ®Google Scholar
• Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM. Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Deliv. 2015;22(5):647–651. doi:10.3109/10717544.2013.86050224283392
   PubMed Web of Science ®Google Scholar
• Dubey RD, Alam N, Saneja A, et al. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. Int J Pharm. 2015;492(1–2):80–91. doi:10.1016/j.ijpharm.2015.07.01226165611
   PubMed Web of Science ®Google Scholar
• Ji S, Xu J, Zhang B, et al. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Biol Ther. 2012;13(4):206–215. doi:10.4161/cbt.13.4.1869222354009
   PubMed Web of Science ®Google Scholar
• Gamble LJ, Borovjagin AV, Matthews QL. Role of RGD-containing ligands in targeting cellular integrins: applications for ovarian cancer virotherapy (Review). Exp Ther Med. 2010;1(2):233–240. doi:10.3892/etm_0000003721494315
   PubMed Web of Science ®Google Scholar
• Chakravarty R, Chakraborty S, Dash A. Molecular imaging of breast cancer: role of RGD peptides. Mini Rev Med Chem. 2015;15(13):1073–1094.26349490
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961–2973. doi:10.1021/mp300273322967287
   PubMed Web of Science ®Google Scholar
• Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands – design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem. 2007;7:552–558. doi:10.2174/18715200778166870617896915
   PubMed Web of Science ®Google Scholar
• Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002;62:5139–5143.12234975
   PubMed Web of Science ®Google Scholar
• Han H, Valdepérez D, Jin Q, et al. Dual enzymatic reaction-assisted gemcitabine delivery systems for programmed pancreatic cancer therapy. ACS Nano. 2017;11(2):1281–1291. doi:10.1021/acsnano.6b0554128071891
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Onda T, Yaegashi N. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Jpn J Clin Oncol. 2015;45(5):408–410. doi:10.1093/jjco/hyv01425765457
   PubMed Web of Science ®Google Scholar
• Mei L, Fu L, Shi K, et al. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int J Pharm. 2014;468(1–2):26–38. doi:10.1016/j.ijpharm.2014.04.00824709209
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182–195. doi:10.1016/j.jconrel.2010.04.02020226220
   PubMed Web of Science ®Google Scholar
• Yang G, Sun H, Kong Y, Hou G, Han J. Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice. Nucl Med Biol. 2014;41(10):856–862. doi:10.1016/j.nucmedbio.2014.08.00825195014
   PubMed Web of Science ®Google Scholar